“I hope you have enjoyed this initial installment of the blog section of the website. Please return frequently as we explore together this complex disease as we move closer and closer to finding new therapeutics and even a cure. I hope to be able to provide you with highlights from the literature and practice as well as a window on exciting new developments coming soon!”
As a physician, maximizing patient health has been my life’s focus. My true passion, however, has always been to invent disruptive technology to expand the frontiers of medical care and enhance patient outcomes.
The moment I unlocked the medical advancement that allowed the discovery of the unique myoelectrical fingerprint of endometriosis, I knew that it would be a game changer for women everywhere.
The effect on me was both humbling and profoundly exhilarating as well as energizing. I hope you have enjoyed this initial installment of the Endometriosis blog section of the website. Please return frequently as we explore together this complex disease, endometriosis, and move closer and closer to finding new therapeutics and even a cure. I hope to be able to provide you with highlights from the literature and practice as well as a window on exciting new developments coming soon!”
ABOUT US
ENDOSURE, INC. offers the only non-invasive, 30-minute, highly accurate diagnosis test for endometriosis that not only fills the gap, but addresses the vacuum in this area of women’s health care.*
© February 2025 ENDOSURE, INC. All rights reserved
1. Approximately 15-20 minutes of patient preparation time may be required prior to performing the test.
2. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
3. i. Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024 May 13;13(10):2866. doi: 10.3390/jcm13102866. PMID: 38792407; PMCID: PMC11122642.
4. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Viganò, P. Endometriosis. Nat. Rev. Dis. Primers. 2018:4-9.
5. 1. Noar M, Mathias J, Kolatkar A. Validation of New GIMA Biomarker Signature of Endometriosis - Interim Data: Research Article. TechRxiv. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
6. 1. Kitsantas P, Benson KN, Al-Farauki S, Knecht MK, Hennekens CH, et al. (2024) Emerging Diagnostic Tools for the Early Diagnosis of Endometriosis. J Reprod Med Gynecol Obstet 9: 171.
DISCLAIMER: THE ENDOSURE TEST IS A DIAGNOSTIC TOOL INTENDED TO INFORM AND ENHANCE A HEALTHCARE PROVIDER'S DECISION-MAKING PROCESS, WHICH IS INDIVIDUALIZED FOR EACH PATIENT'S CIRCUMSTANCES AND TAKE INTO ACCOUNT THE FULL SCOPE OF MEDICAL DATA AND INFORMATION AVAILABLE TO THE PROVIDER. THE ENDOSURE TEST IS NOT INTENDED TO SUBSTITUTE, REPLACE, OVERRULE, OR DIRECT A HEALTHCARE PROVIDER’S JUDGMENT.
* USA CUSTOMERS: EndoSure is currently available for research in the USA use only and not clinical use.